BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 25760429)

  • 1. SMAD4 expression predicts local spread and treatment failure in resected pancreatic cancer.
    Yamada S; Fujii T; Shimoyama Y; Kanda M; Nakayama G; Sugimoto H; Koike M; Nomoto S; Fujiwara M; Nakao A; Kodera Y
    Pancreas; 2015 May; 44(4):660-4. PubMed ID: 25760429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer.
    Oshima M; Okano K; Muraki S; Haba R; Maeba T; Suzuki Y; Yachida S
    Ann Surg; 2013 Aug; 258(2):336-46. PubMed ID: 23470568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Failure patterns in resected pancreas adenocarcinoma: lack of predicted benefit to SMAD4 expression.
    Winter JM; Tang LH; Klimstra DS; Liu W; Linkov I; Brennan MF; DʼAngelica MI; DeMatteo RP; Fong Y; Jarnagin WR; Oʼreilly EM; Allen PJ
    Ann Surg; 2013 Aug; 258(2):331-5. PubMed ID: 23360922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of SMAD4 staining in pre-operative cell blocks is associated with distant metastases following pancreaticoduodenectomy with venous resection for pancreatic cancer.
    Boone BA; Sabbaghian S; Zenati M; Marsh JW; Moser AJ; Zureikat AH; Singhi AD; Zeh HJ; Krasinskas AM
    J Surg Oncol; 2014 Aug; 110(2):171-5. PubMed ID: 24665063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intratumoral Heterogeneity of SMAD4 Immunohistochemical Expression and Its Role in Prediction of Recurrence Pattern in Patients with Resectable Pancreatic Cancer.
    Pokataev I; Kudaibergenova A; Artemyeva A; Popova A; Rumyantsev A; Podluzhny D; Kudashkin N; Fedyanin M; Tryakin A; Tjulandin S
    J Gastrointest Cancer; 2019 Sep; 50(3):478-484. PubMed ID: 29675723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decreased TIP30 expression predicts poor prognosis in pancreatic cancer patients.
    Guo S; Jing W; Hu X; Zhou X; Liu L; Zhu M; Yin F; Chen R; Zhao J; Guo Y
    Int J Cancer; 2014 Mar; 134(6):1369-78. PubMed ID: 24037692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pattern of Invasion in Human Pancreatic Cancer Organoids Is Associated with Loss of SMAD4 and Clinical Outcome.
    Huang W; Navarro-Serer B; Jeong YJ; Chianchiano P; Xia L; Luchini C; Veronese N; Dowiak C; Ng T; Trujillo MA; Huang B; Pflüger MJ; Macgregor-Das AM; Lionheart G; Jones D; Fujikura K; Nguyen-Ngoc KV; Neumann NM; Groot VP; Hasanain A; van Oosten AF; Fischer SE; Gallinger S; Singhi AD; Zureikat AH; Brand RE; Gaida MM; Heinrich S; Burkhart RA; He J; Wolfgang CL; Goggins MG; Thompson ED; Roberts NJ; Ewald AJ; Wood LD
    Cancer Res; 2020 Jul; 80(13):2804-2817. PubMed ID: 32376602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of Zinc finger E-box binding homeobox 1 (ZEB1) expression in cancer cells and cancer-associated fibroblasts in pancreatic head cancer.
    Bronsert P; Kohler I; Timme S; Kiefer S; Werner M; Schilling O; Vashist Y; Makowiec F; Brabletz T; Hopt UT; Bausch D; Kulemann B; Keck T; Wellner UF
    Surgery; 2014 Jul; 156(1):97-108. PubMed ID: 24929761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Poorly differentiated histologic grade correlates with worse survival in SMAD4 negative pancreatic adenocarcinoma patients.
    Park JY; King J; Reber H; Joe Hines O; Mederos MA; Wang HL; Dawson D; Wainberg Z; Donahue T; Girgis M
    J Surg Oncol; 2021 Feb; 123(2):389-398. PubMed ID: 33146409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TM4SF1 as a prognostic marker of pancreatic ductal adenocarcinoma is involved in migration and invasion of cancer cells.
    Zheng B; Ohuchida K; Cui L; Zhao M; Shindo K; Fujiwara K; Manabe T; Torata N; Moriyama T; Miyasaka Y; Ohtsuka T; Takahata S; Mizumoto K; Oda Y; Tanaka M
    Int J Oncol; 2015 Aug; 47(2):490-8. PubMed ID: 26035794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DPC4/Smad4 expression and outcome in pancreatic ductal adenocarcinoma.
    Biankin AV; Morey AL; Lee CS; Kench JG; Biankin SA; Hook HC; Head DR; Hugh TB; Sutherland RL; Henshall SM
    J Clin Oncol; 2002 Dec; 20(23):4531-42. PubMed ID: 12454109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term outcome of portomesenteric vein invasion and prognostic factors in pancreas head adenocarcinoma.
    Jeong J; Choi DW; Choi SH; Heo JS; Jang KT
    ANZ J Surg; 2015 Apr; 85(4):264-9. PubMed ID: 24641800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intrapancreatic nerve invasion as a predictor for recurrence after pancreaticoduodenectomy in patients with invasive ductal carcinoma of the pancreas.
    Shimada K; Nara S; Esaki M; Sakamoto Y; Kosuge T; Hiraoka N
    Pancreas; 2011 Apr; 40(3):464-8. PubMed ID: 21289526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD24 and S100A4 expression in resectable pancreatic cancers with earlier disease recurrence and poor survival.
    Lee SH; Kim H; Hwang JH; Shin E; Lee HS; Hwang DW; Cho JY; Yoon YS; Han HS; Cha BH
    Pancreas; 2014 Apr; 43(3):380-8. PubMed ID: 24622067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Superior mesenteric artery margin in pancreaticoduodenectomy for pancreatic adenocarcinoma.
    Liu DN; Lv A; Tian ZH; Tian XY; Guan XY; Dong B; Zhao M; Hao CY
    Oncotarget; 2017 Jan; 8(5):7766-7776. PubMed ID: 27999192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infiltrating immune cells and gene mutations in pancreatic ductal adenocarcinoma.
    Wang WQ; Liu L; Xu HX; Wu CT; Xiang JF; Xu J; Liu C; Long J; Ni QX; Yu XJ
    Br J Surg; 2016 Aug; 103(9):1189-99. PubMed ID: 27256393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Splenic artery invasion in pancreatic adenocarcinoma of the body and tail: a novel prognostic parameter for patient selection.
    Partelli S; Crippa S; Barugola G; Tamburrino D; Capelli P; D'Onofrio M; Pederzoli P; Falconi M
    Ann Surg Oncol; 2011 Dec; 18(13):3608-14. PubMed ID: 21584836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histopathological tumor invasion of the mesenterico-portal vein is characterized by aggressive biology and stromal fibroblast activation.
    Lapshyn H; Bolm L; Kohler I; Werner M; Billmann FG; Bausch D; Hopt UT; Makowiec F; Wittel UA; Keck T; Bronsert P; Wellner UF
    HPB (Oxford); 2017 Jan; 19(1):67-74. PubMed ID: 27825542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pancreatectomy combined with superior mesenteric-portal vein resection: report of 32 cases.
    Zhou GW; Wu WD; Xiao WD; Li HW; Peng CH
    Hepatobiliary Pancreat Dis Int; 2005 Feb; 4(1):130-4. PubMed ID: 15730937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphatase PPM1A is a novel prognostic marker in pancreatic ductal adenocarcinoma.
    Fan J; Yang MX; Ouyang Q; Fu D; Xu Z; Liu X; Mino-Kenudson M; Geng J; Tang F
    Hum Pathol; 2016 Sep; 55():151-8. PubMed ID: 27195906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.